BackGuobang Pharma Overview

Guobang Pharma Receivables

Track Guobang Pharma's receivables ($1.4B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.37B
↓ 4.62% YoYΔ $-66.53M vs prior year quarter

Peer trimmed avg / median

Loading

Guobang Pharma Receivables History

Loading

Guobang Pharma vs. peers: Receivables Comparison

Loading

Guobang Pharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Guobang Pharma (605507.SS) FAQ

As of the most recent data (September 2026), 605507.SS shows a receivables of $1.4B. That compares with $1.4B in the prior-year period — down 4.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 605507.SS's receivables is now $1.4B (was $1.4B) — a 4.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Guobang Pharma is outperforming or lagging.

Tracking 605507.SS's receivables over time shows whether Guobang Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $1.4B That compares with $1.4B in the prior-year period — down 4.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Guobang Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $1.4B) with ownership activity and broader fundamentals.